GCOM1: A Potential Drug Target and Biomarker for Myocardial Zonula Adherens Protein

Target Name: GCOM1

NCBI ID: G145781

GCOM1

GCOM1: A Potential Drug Target and Biomarker for Myocardial Zonula Adherens Protein

Myocardial zonula adherens protein (GCOM1) is a protein that plays a crucial role in the structure and function of heart muscle cells. It is a member of the zonula adherens complex (ZAC), which is a network of proteins that help to maintain the integrity of heart muscle cells. Mutations in GCOM1 have been linked to a range of cardiovascular diseases, including heart failure, hypertension, and sudden cardiac death.

GCOM1 is a transmembrane protein that is expressed in the heart muscle. It is composed of four structural domains: a N-terminal transmembrane domain, a T-terminal adherens domain, a D1 domain, and a C-terminal T-loop domain. The N-terminal and T-terminal domains give GCOM1 its unique structure and function.

The N-terminal domain of GCOM1 is composed of a unique fenestral domain that is involved in the formation of the ZAC. The T-terminal domain is involved in the formation of a hydrophobic tunnel that connects the ZAC to the cytoskeleton. The D1 and C -Terminal domains are involved in the formation of the ZAC and the maintenance of the ZAC's integrity.

GCOM1 is involved in the regulation of a variety of cellular processes that are important for heart function. It plays a role in the regulation of ion channels, including the cardiac sodium channels that regulate the flow of electrical signals through the heart muscle. It is also involved in the regulation of the contraction and relaxation of heart muscle cells, as well as the regulation of the cytoskeleton.

In addition to its role in the regulation of heart function, GCOM1 is also a potential drug target. Studies have shown that GCOM1 is highly expressed in various tissues and that it is involved in the development and progression of a variety of cardiovascular diseases, including heart failure, hypertension, and sudden cardiac death.

One of the potential reasons why GCOM1 is a drug target is because of its role in the regulation of the cytoskeleton. GCOM1 is involved in the formation of the ZAC, which is a network of proteins that help to maintain the integrity of heart muscle cells. The ZAC is composed of a variety of proteins that are involved in the regulation of cell signaling pathways, including the regulation of ion channels and the regulation of the cytoskeleton.

GCOM1 is also involved in the regulation of the cytoskeleton in a variety of ways. For example, it is involved in the regulation of the attachment of the cytoskeleton to the endoplasmic reticulum, which is the process by which proteins are transported from the cytoskeleton to the endoplasmic reticulum. It is also involved in the regulation of the organization of the cytoskeleton in the cell, which is important for the proper functioning of the heart muscle.

In addition to its role in the regulation of the cytoskeleton, GCOM1 is also involved in the regulation of cell signaling pathways. It is involved in the regulation of the regulation of the cytoskeleton, which is the process by which the cytoskeleton is modified to regulate the movement of the cell. It is also involved in the regulation of the regulation of the cytoskeleton, which is the process by which the cytoskeleton is modified to regulate the movement of the cell.

GCOM1 is also involved in the regulation of the regulation of the cytoskeleton in a variety of ways. For example, it is involved in the regulation of the attachment of the cytoskeleton to the endoplasmic reticulum, which is the process by which proteins are transported from the cytoskeleton to the endoplasmic reticulum. It is also involved in the regulation of the organization of the cytoskeleton in the cell, which is important for the proper functioning of the heart muscle.

GCOM1 is also a potential biomarker for

Protein Name: GCOM1, MYZAP-POLR2M Combined Locus

The "GCOM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCOM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets